Omeprazole Capsule Multiple Dose/Steady State BE Requirement [Design Issues]

posted by Relaxation  – Germany, 2017-12-07 16:50 (2303 d 20:26 ago) – Posting: # 18041
Views: 2,773

Hello everybody.

Just a short input as I do not fully agree with the answer.

❝ Normally, Single dose fasting and fed studies are required.

Would be my answer, too.

❝ Reason may be, omeprazole has time-dependent kinetics (omeprazole auto-inhibits its metabolism). ❝ Hence, according to Guidance on the investigation of Bioavailability and Bioequivalence, a

❝ steady state study is required due to this time dependency.


Would it be possible to point to the guideline you are referring and maybe the page? I mean, I could follow that argument if the task was to clarify the pharmacokinetics of a product.
But in case of bioequivalence I fail to understand the need for a study at steady-state (and also fail to find that requirement in the guidelines I am aware of).

OK, if this was a prolonged release formulation, but, um, do such formulations for omeprazole exist :confused:.

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
103 visitors (0 registered, 103 guests [including 8 identified bots]).
Forum time: 13:17 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5